Evaluation of accelerator mass spectrometry in a human mass balance and pharmacokinetic study-experience with 14C-labeled (R)-6-[amino(4- chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1- methyl-2(1H)-quinolinone (R115777), a farnesyl transferase inhibitor.

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Drug Metabolism And Disposition

• Publication date

  2002-07-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1124/DMD.30.7.823PMID 12065441
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Mass Spectrometry Innovations in Drug Discovery and Development

  2001cited by this paper
• Accelerator mass spectrometry (AMS): recent experience of its use in a clinical study and the potential future of the technique

  2001cited by this paper
• A Mass Balance Study to Evaluate the Biotransformation and Excretion of [14C]‐Triamcinolone Acetonide following Oral Administration

  2000cited by this paper
• Analysis of DNA adducts by accelerator mass spectrometry in human breast tissue after administration of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine and benzo[a]pyrene.

  2000cited by this paper
• Accelerator mass spectrometry in pharmaceutical research and development--a new ultrasensitive analytical method for isotope measurement.

  2000cited by this paper
• A validation study comparing accelerator MS and liquid scintillation counting for analysis of 14C-labelled drugs in plasma, urine and faecal extracts.

  2000cited by this paper
• Pushing the accelerator – speeding up drug research with accelerator mass spectrometry

  2000cited by this paper
• Bioanalytical applications of accelerator mass spectrometry for pharmaceutical research.

  2000cited by this paper
• Comparison of DNA‐adduct and tissue‐available dose levels of MeIQx in human and rodent colon following administration of a very low dose

  1999cited by this paper
• Biomedical applications of accelerator mass spectrometry-isotope measurements at the level of the atom.

  1999cited by this paper
• Accelerator mass spectrometry and its applications

  1999cited by this paper
• Disposition and metabolism of 14C-rifapentine in healthy volunteers.

  1998cited by this paper
• A preliminary evaluation of accelerator mass spectrometry in the biomedical field.

  1997cited by this paper
• Biomedical accelerator mass spectrometry

  1995cited by this paper
• Accelerator mass spectrometry.

  1995cited by this paper
• Accelerator mass spectrometry : isotope quantification at attomole sensitivity

  1995cited by this paper
• A Regulatory and Industrial Perspective of the Use of Carbon-14 and Tritium Isotopes in Human ADME Studies

  1994cited by this paper
• Rapid Production of Graphite Without Contamination for Biomedical AMS

  1992cited by this paper
• Carbon-14: Direct Detection at Natural Concentrations

  1977cited by this paper
• Radiocarbon Dating Using Electrostatic Accelerators: Negative Ions Provide the Key

  1977cited by this paper

• Special Section on Perspective on Drug Metabolism and Disposition, Part I — Minireview Human Absorption, Distribution, Metabolism, and Excretion Studies: Origins, Innovations, and Importance S

  2023cites this paper
• Absorption, distribution, metabolism and excretion of an isocitrate dehydrogenase-2 inhibitor enasidenib in rats and humans

  2019cites this paper
• Absorption, distribution, metabolism, and excretion of mTOR kinase inhibitor CC-223 in rats, dogs, and humans

  2019cites this paper
• A phase I, open-label, single-dose micro tracer mass balance study of 14C-labeled ASP7991 in healthy Japanese male subjects using accelerator mass spectrometry.

  2018cites this paper
• METABOLITE TECHNOLOGY: QUALITATIVE AND QUANTITATIVE

  2016cites this paper
• Pharmacokinetic Interactions in Combination Therapies for Acute Myeloid Leukemia

  2016cites this paper
• Quantitation of Drug Metabolites by Radioactivity Detection Including Accelerator Mass Spectrometry (AMS)

  2014cites this paper
• Use of Microdosing and Accelerator Mass Spectrometry To Evaluate the Pharmacokinetic Linearity of a Novel Tricyclic GyrB/ParE Inhibitor in Rats

  2014cites this paper
• Disposition and Metabolic Profiling of [14C]Cerlapirdine Using Accelerator Mass Spectrometry

  2014cites this paper
• Molecular Inhibitors of Growth Signals

  2014cites this paper
• 22. Radioactivity Profiling

  2012cites this paper
• Preclinical metabolism of LB42908, a novel farnesyl transferase inhibitor, and its effects on the cytochrome P450 isozyme activities.

  2012cites this paper
• Meeting the MIST regulations: human metabolism in Phase I using AMS and a tiered bioanalytical approach.

  2012cites this paper
• Radiolabeled absorption, distribution, metabolism, and excretion studies in drug development: why, when, and how?

  2012cites this paper
• Applications of Accelerator Mass Spectrometry (AMS)

  2012cites this paper
• Predicting Human Biotransformation Pathways

  2012cites this paper
• Metabolite Testing in Drug Development

  2011cites this paper
• The use of accelerator MS in support of MIST.

  2011cites this paper
• From definition to implementation: a cross-industry perspective of past, current and future MIST strategies

  2011cites this paper
• Quantitative Drug Metabolism with Accelerator Mass Spectrometry

  2011cites this paper
• Microdosing: Pharmacokinetic and Metabolism Data Early in the Drug Development Process

  2011cites this paper
• Accelerator mass spectrometry in the attomolar concentration range for 14C-labeled biologically active compounds in complex matrixes

  2010cites this paper
• Accelerator mass spectrometry-enabled studies: current status and future prospects.

  2010cites this paper
• Metabolism and Disposition of [14C]BMS-690514, an ErbB/Vascular Endothelial Growth Factor Receptor Inhibitor, after Oral Administration to Humans

  2010cites this paper
• Microdose Study of 14C‐Acetaminophen With Accelerator Mass Spectrometry to Examine Pharmacokinetics of Parent Drug and Metabolites in Healthy Subjects

  2010cites this paper
• Uridine 5'-diphospho-glucuronosyltransferase genetic polymorphisms and response to cancer chemotherapy.

  2010cites this paper
• Looking back through the MIST: a perspective of evolving strategies and key focus areas for metabolite safety analysis.

  2010cites this paper
• Microdosing: a valuable tool for accelerating drug development and the role of bioanalytical methods in meeting the challenge.

  2009cites this paper
• Pharmacotherapy of Hematologic Malignancies with Tipifarnib

  2009cites this paper
• Metabolites in safety testing: metabolite identification strategies in discovery and development.

  2009cites this paper
• Pharmaceutical Applications of Accelerator Mass Spectrometry

  2009cites this paper
• A holistic strategy for characterizing the safety of metabolites through drug discovery and development.

  2009cites this paper
• A pharmacokinetic evaluation of five H(1) antagonists after an oral and intravenous microdose to human subjects.

  2009cites this paper
• Metabolite Identification Strategies and Procedures

  2009cites this paper
• Use of an intravenous microdose of 14C-labeled drug and accelerator mass spectrometry to measure absolute oral bioavailability in dogs; cross-comparison of assay methods by accelerator mass spectrometry and liquid chromatography-tandem mass spectrometry.

  2009cites this paper
• Biotransformation profiling of [(14)C]ixabepilone in human plasma, urine and feces samples using accelerator mass spectrometry (AMS).

  2009cites this paper
• In vitro screening techniques for reactive metabolites for minimizing bioactivation potential in drug discovery.

  2008cites this paper
• Applications of High‐Sensitivity Mass Spectrometry and Radioactivity Detection Techniques in Drug Metabolism Studies

  2008cites this paper
• Radioactivity Detectors for High-Performance Liquid Chromatography in Drug Metabolism Studies

  2008influential citation
• Phase I trial of tipifarnib in children with newly diagnosed intrinsic diffuse brainstem glioma.

  2008cites this paper
• Pharmacokinetic Studies in Microdosing and Phase 0 Trials

  2008cites this paper
• Microdosing Studies in Humans

  2008cites this paper
• Microdosing studies in humans: the role of positron emission tomography.

  2008cites this paper
• What is the Objective of the Mass Balance Study? A Retrospective Analysis of Data in Animal and Human Excretion Studies Employing Radiolabeled Drugs

  2007influential citation
• American College of Clinical Pharmacology Position Statement on the Use of Microdosing in the Drug Development Process

  2007cites this paper
• Analytical strategies for identifying drug metabolites.

  2007cites this paper
• Unexplored Pharmacokinetic Opportunities with Microdosing in Oncology 55 Commentary on Boddy et al . , p . 4164

  2007cites this paper
• Cytostar-T plates--a valid alternative for microplate scintillation counting of low radioactivity in combination with high-performance liquid chromatography in drug metabolism studies?

  2007cites this paper
• Development Process American College of Clinical Pharmacology Position Statement on the Use of Microdosing in the Drug

  2007cites this paper
• Unexplored Pharmacokinetic Opportunities with Microdosing in Oncology

  2007cites this paper
• Human mass balance study of the novel anticancer agent ixabepilone using accelerator mass spectrometry

  2007cites this paper
• STRATEGIES FOR IDENTIFYING DRUG METABOLITES

  2007cites this paper
• Use of microdosing to predict pharmacokinetics at the therapeutic dose: Experience with 5 drugs

  2006cites this paper
• Mass Balance Studies, with a Focus on Anticancer Drugs

  2006cites this paper
• Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study.

  2006cites this paper
• Applications of accelerator mass spectrometry for pharmacological and toxicological research.

  2006cites this paper
• Pharmacokinetics of Tipifarnib After Oral and Intravenous Administration in Subjects With Advanced Cancer

  2006influential citation
• EVALUATION OF MICRODOSING TO ASSESS PHARMACOKINETIC LINEARITY IN RATS USING LIQUID CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY

  2006cites this paper
• Biomedical Accelerator Mass Spectrometry

  2006cites this paper
• Phase I trial of tipifarnib in patients with recurrent malignant glioma taking enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study.

  2005influential citation
• ライフサイエンスのためのアイソトープ測定機器 (第四シリーズ) VI.加速器質量分析 (AMS) の薬物動態試験への応用研究

  2005cites this paper
• The Application of Accelerator Mass Spectrometry to Absolute Bioavailability Studies in Humans: Simultaneous Administration of an Intravenous Microdose of 14C‐Nelfinavir Mesylate Solution and Oral Nelfinavir to Healthy Volunteers

  2005cites this paper
• Development of farnesyl transferase inhibitors: a review.

  2005cites this paper
• Mechanisms of resistance to anticancer drugs: the role of the polymorphic ABC transporters ABCB1 and ABCG2.

  2005cites this paper
• Phytochemical research using accelerator mass spectrometry.

  2004cites this paper
• Current perspectives of 14C-isotope measurement in biomedical accelerator mass spectrometry

  2004cites this paper
• Pharmacogenetics of tipifarnib (R115777) transport and metabolism in cancer patients

  2004cites this paper
• Phytochemical Research Using Accelerator Mass

  2004cites this paper
• Methods to assess tissue-specific distribution and metabolism of drugs.

  2004cites this paper
• The use of radiolabeled compounds for ADME studies in discovery and exploratory development.

  2004cites this paper
• Phase I and pharmacokinetic study of irinotecan in combination with R115777, a farnesyl protein transferase inhibitor

  2004cites this paper
• EVALUATION OF MICRODOSING STRATEGIES FOR STUDIES IN PRECLINICAL DRUG DEVELOPMENT: DEMONSTRATION OF LINEAR PHARMACOKINETICS IN DOGS OF A NUCLEOSIDE ANALOG OVER A 50-FOLD DOSE RANGE

  2004influential citation
• Chapter 11 - Ultra-sensitive detection of radiolabelled drugs and their metabolites using accelerator mass spectrometry

  2003cites this paper
• Big physics, small doses: the use of AMS and PET in human microdosing of development drugs

  2003cites this paper
• Liquid chromatography/atmospheric pressure ionization-mass spectrometry in drug metabolism studies.

  2003cites this paper
• Current trends in modern pharmaceutical analysis for drug discovery.

  2003cites this paper
• UGT pharmacogenomics: implications for cancer risk and cancer therapeutics.

  2003cites this paper
• Pharmacogenomics of ABC transporters and its role in cancer chemotherapy.

  2003cites this paper
• Current literature in mass spectrometry.

  2002cites this paper